This technician at a microscope demonstrates Denali’s focus on investigating new oral therapies for Parkinson’s disease

Potential treatment for people living with Parkinson’s

Denali is investigating an innovative, oral treatment called DNL151 that aims to slow disease progression and treat the underlying cause of the disease.

Our approach to treatment development in Parkinson’s includes engineering potential therapies that may target the brain to address the underlying cause of the disease. We are also using various biological markers to support our understanding of the treatment and its potential effects.

DNL151 is an investigational drug and is not approved by any Health Authority